Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma-Reference-Cited by-同舟云学术

Interim report of a phase 2 clinical trial of lenalidomide for T-cell non-Hodgkin lymphoma

Published:2010-08-19 Issue:19 Volume:116 Page:4541-4548
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Dueck Greg,Chua Neil,Prasad Angeli,Finch Daygen,Stewart Doug,White Darrell,van der Jagt Richard,Johnston James,Belch Andrew,Reiman Tony

Publisher

Wiley

Subject

Cancer Research,Oncology

Reference45 articles.

1. Evaluation of the Revised European-American Lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma;Melnyk;Blood,1997

2. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA);Gisselbrecht;Blood,1998

3. Peripheral T-cell lymphomas: initial features, natural history, and prognostic factors in a series of 174 patients diagnosed according to the R.E.A.L. Classification;Lopez-Guillermo;Ann Oncol,1998

4. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study;Gallamini;Blood,2004

5. Hepatosplenic gammadelta T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients;Belhadj;Blood,2003

Cited by 90 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel clinical risk stratification and treatment strategies in relapsed/refractory peripheral T-cell lymphoma;Journal of Hematology & Oncology;2024-06-01

2. Population pharmacokinetics of lenalidomide in Chinese patients with influence of genetic polymorphisms of ABCB1;Scientific Reports;2024-01-31

3. Past, present and future therapeutic approaches in nodal peripheral T-cell lymphomas;Haematologica;2023-11-21

4. Population pharmacokinetics of lenalidomide in Chinese patients with influence of genetic polymorphisms of ABCB1;2023-10-17

5. Controversies in the Front-Line Treatment of Systemic Peripheral T Cell Lymphomas;Cancers;2022-12-30